An ex-vivo pharmacodynamic study comparing bactericidal activity of amoxicillin/sulbactam, azithromycin, doxycycline and levofloxacin against Streptococcus pneumoniae

Journal of Chemotherapy

Volumn 16, Issue 3, 2004, Pages 248-254

  Bantar, C ^a,e   Nicola, F ^b   Arenoso, H ^c   Soutric, J ^c   Caruso, N ^c   Fernandez Canigia L ^d  

^a Laboratorio Domingo I Nanni   (Argentina)

^b Laboratorio Mutual Banco Provincia   (Argentina)

^c Laboratorios Bago   (Argentina)

^d HOSPITAL ALEMÁN   (Argentina)

^e NONE   (Argentina)

Author keywords

Amoxicillin sulbactam; Azithromycin; Community acquired pneumonia; Doxycycline; Levofloxacin; Pharmacodynamics; S. pneumoniae

Indexed keywords

AMOXICILLIN PLUS SULBACTAM; ANTIBIOTIC AGENT; AZITHROMYCIN; DOXYCYCLINE; LEVOFLOXACIN; TRIFAMOX IBL DUO; UNCLASSIFIED DRUG; VIBRAMICINA;

ADULT; ARTICLE; BACTEREMIA; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CELL VIABILITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; EX VIVO STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; INCUBATION TIME; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORMAL HUMAN; PHARMACODYNAMICS; STREPTOCOCCUS PNEUMONIAE; TABLET; VENOUS BLOOD;

EID: 3843105913     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2004.16.3.248     Document Type: Article

References (31)

1. Bantar C, Bavestrello L, Curcio D et al. Acute community-acquired pneumonia in adults: guidelines for initial antimicrobial therapy based on local evidence from a South American Working Group (ConsenSur). J Chemother 2002; 14 (Suppl 4): 1-22.
2. Bartlett JG, Dowell SF, Mandell LA et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-382.
3. Mandell LA, Marrie TJ, Grossman RF et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000; 31: 383-421.
4. Huchon G, & European Study on Community-Acquired Pneumonia. Guidelines for management of adult community-acquired lower respiratory tract infections. Eur Resp J 1998; 11: 986-991.
5. Niederman MS, Mandell LA, Anzueto A et al. Guidelines for management of adults with community-acquired pneumonia. Am J Resp Clin Care Med 2001; 163: 1730-1754.
6. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001; 56 (Suppl 4): iv1-iv64.
7. Kelley MA, Weber DJ, Gilligan P et al. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31: 1008-1011.
8. Lisby G, Brasholt MS, Teglbjerg M.. Bacteremia and meningitis caused by a macrolide-sensitive strain of Streptococcus pneumoniae during treatment with azithromycin. Clin Infect Dis 2001; 33: 415-416.
9. Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2000; 35: 556-564.
10. Davidson R, Cavalcanti R, Brunton JL et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. New Eng J Med 2002; 346: 747-750.
11. Ross JJ, Worthington MG, Gorbach SL. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia [letter]. New Eng J Med 2002; 347: 65-66.
12. Bishai W. The in vivo-in vitro paradox in pneumococcal respiratory tract infection. J Antimicrob Chemother 2002. 49: 433-436.
13. Bantar C, Nicola F, Fernandez Canigia L et al. A pharmacodynamic model to support a twelve-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections. J Chemother 2000; 12: 223-227.
14. Jasovich A, Soutric J, Morera G et al. Efficacy of amoxicillin-sulbactam, given twice-a-day, for the treatment of community- acquired pneumonia. A clinical trial based on a pharmacodynamic model. J Chemother 2002; 14: 591-596.
15. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard M7-A5. 2000. National Committee for Clinical Laboratory Standards, Villanova, Pa.
16. den Hollander JG, Knudsen JD, Mouton WJ et al. Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo. Antimicrob Agents Chemother 1998; 42: 377-382.
17. Ruhen RW, Tandon MK. Minocycline, doxycycline and tetracycline levels in serum and bronchial secretions of patients with chronic bronchitis. Pathology 1975; 7: 193-197
18. Sakellari D, Goodson JM, Kolokotronis A et al. Concentration of 3 tetracyclines in plasma, gingival crevice fluid and saliva. J Clin Periodontol 2000; 27: 53-60
19. Berry V, Thorbum CE, Knott SJ, et al. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob Agents Chemother 1998; 42: 3193-3199.
20. Musher DM, Dowell ME, Shortridge VD et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia [letter]. N Engl J Med 2002; 346: 630-631.
21. Joshi N, Miller DO. Doxycycline revisited. Arch Intern Med 1997; 157: 1421-1428.
22. Tice AD. Doxycycline: new ways to use an old antibiotic [letter]. Arch Intern Med 1998; 158: 928-929.
23. Ailani RK, Agastya G, Ailani RK et al. Doxycycline is a cost-effective therapy for hospitalized patients with community- acquired pneumonia. Arch Intern Med 1999; 159: 266-270.
24. Ditmanson L, Apgar D, Tuscon A. Treatment for community acquired pneumonia: more support for doxycycline [letter]. Arch Intern Med 1999; 159: 1814-1815.
25. Shah PM. Serum bactericidal activity of levofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 1999; 43 (Suppl. C): 61-65.
26. Lister PD, Sanders CC. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 1999; 43: 79-86.
27. Ho PL, Tse WS, Tsang KW et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001; 32: 701-707.
28. Craig WA. Pharmacokinetic/pharmacodynamic parameter: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1997; 26: 1-12.
29. Calver A, Walsh N, Quinn P et al. Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection. Clin Infect Dis 1997; 24: 570-574.
30. Masson JM, Kazmierczak A, Labia R. Interactions of clavulanic acid and sulbactam with penicilin-binding proteins. Drugs Exp Clin Res 1983; 9: 513-518.
31. Carsenti-Etesse H, Duran J, De Salvador F, et al. Possible prevention of in vitro selection of resistant Streptococcus pneumoniae by beta-lactamase inhibitors. Eur J Clin Microbiol Infect Dis 1994; 13: 1058-1062.